End-of-treatment data from ENRICH demonstrated higher HBsAg loss rates, consistent with ENSURE Cohort 4, confirming the role of BRII-179 in priming immune responses for functional cure strategies
End-of-treatment data from ENHANCE did not demonstrate improved HBsAg loss rates compared to ENSURE Cohorts 2 and 3, informing selection of combination regimen going forward
As previously disclosed, advancement of ENRICH into Phase 3 remains subject to the outcome of arbitration with Vir Biotechnology regarding the elebsiran manufacturing technology transfer
DURHAM, N.C. and BEIJING, July 3, 2026 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical need, today announced end-of-treatment (EOT) results from its ongoing Phase 2b ENRICH and ENHANCE studies investigating sequential versus concurrent combination regimens of BRII-179 with elebsiran and PEG-IFNα for chronic hepatitis B virus (HBV) infection.
The ENRICH and ENHANCE studies are two Phase 2b studies designed to further define the role of BRII-179 in chronic HBV treatment and to select the optimal combination regimen for future development. The ENRICH study evaluates BRII-179 as a priming therapy administered prior to elebsiran and PEG-IFNα treatment. The ENHANCE study evaluates a concurrent triple combination regimen of BRII-179, elebsiran, and PEG-IFNα to enhance the functional cure rates.
At EOT, the ENRICH study evaluating pre-treatment with BRII-179 followed by elebsiran and PEG-IFNα demonstrated hepatitis B surface antigen (HBsAg) loss rates of 42.9% (42/98) and 40.0% (20/50) across two different BRII-179 dosing schedules, being 5 doses administered once every 3 weeks versus 7 doses administered once every 2 weeks, respectively. These results were consistent with the HBsAg loss rate observed in ENSURE Cohort 4, 41.9% (13/31) in patients with prior BRII-179 treatment, supporting the immune priming role of BRII-179. The Company had engaged with the Center for Drug Evaluation of the National Medical Products Administration of China and reached preliminary alignment regarding a potential registrational study.
At EOT, the ENHANCE (Part A-1) study evaluating a concurrent triple combination did not demonstrate improved HBsAg loss rates compared with ENSURE Cohorts 2 and 3, 29.7% (11/37), with an observed rate of 25.5% (25/98). However, higher HBsAg loss rates were observed compared with the PEG-IFNα control arm, 10.2% (5/49).